Genmab A/S, the Danish producer of antibody therapeutics for cancer, expects its 2009 revenue to rise 61% to DKK 1.2 billion following a gain of 41% in 2008. The main reason is the company’s collaboration with GlaxoSmithKline which is producing a hefty stream of milestone payments.
